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RFC (reduced folate carrier) is the major transporter for
reduced folates and antifolates [e.g. MTX (methotrexate)].
RFC is characterized by two halves, each with six TMD
(transmembrane domain) α helices connected by a hydrophilic
loop, and cytoplasmic N- and C-termini. We previously identiﬁed
TMDs 4, 5, 7, 8, 10 and 11 as forming the hydrophilic cavity
for translocation of (anti)folates. The proximal end of TMD8
(positions 311–314) was implicated in substrate binding from
scanning-cysteine accessibility methods; cysteine replacement of
Ser
313 resulted in loss of transport. In the present study, Ser
313 was
mutatedtoalanine,cysteine,phenylalanineandthreonine.Mutant
RFCs were expressed in RFC-null R5 HeLa cells. Replacement
ofSer
313 withcysteineorphenylalanineabolishedMTXtransport,
whereas residual activity was preserved for the alanine and
threonine mutants. In stable K562 transfectants, S313A and
S313T RFCs showed substantially decreased Vmax values without
changes in Kt values for MTX compared with wild-type RFC.
S313A and S313T RFCs differentially impacted binding of ten
diverse (anti)folate substrates. Cross-linking between TMD8 and
TMD5wasstudiedbyexpressingcysteine-lessTMD1–6(N6)and
TMD7–12 (C6) half-molecules with cysteine insertions spanning
thesehelicesinR5cells,followedbytreatmentwiththiol-reactive
homobifunctional cross-linkers. C6–C6 and N6–N6 cross-links
were seen for all cysteine pairs. From the N6 and C6 cysteine
pairs, Cys
175/Cys
311 was cross-linked; cross-linking increased in
the presence of transport substrates. The results of the present
study indicate that the proximal end of TMD8 is juxtaposed to
TMD5 and is conformationally active in the presence of transport
substrates, and TMD8, including Ser
313, probably contributes to
the RFC substrate-binding domain.
Key words: antifolate, cross-linking, folate, major facilitator
superfamily, mutagenesis, oligomer, reduced folate carrier,
transporter.
INTRODUCTION
Folates are members of the B class of vitamins that are co-
factors for the synthesis of nucleotide precursors, serine and
methionine in one-carbon transfer reactions [1]. Mammalian
cells, unlike bacteria, cannot synthesize folates de novo. Hence,
folate requirements must be met entirely from dietary sources
[2,3]. Because of their hydrophilic charged character, there
is minimal passive diffusion of anionic folates across cell
membranes. Accordingly, speciﬁc transporters have evolved to
mediate intestinal absorption of dietary folates, renal tubular
secretion and reabsorption of folates, and transport of circulating
reduced folates into systemic tissues [3].
The ubiquitously expressed RFC (reduced folate carrier) is
considered to be the major transport system for folate co-
factors in mammalian cells and tissues [3,4]. RFC serves a
generalizedroleinfolatetransportandprovidesspecializedtissue
functions [5–9] such that loss of RFC expression or function
may have potentially profound physiological and developmental
consequences associated with folate deﬁciency [10]. RFC is
also a major transporter of antifolate drugs used for cancer
chemotherapy such as MTX (methotrexate), pemetrexed and
raltitrexed [4]. Furthermore, the effectiveness of chemotherapy
with these agents is closely linked to levels and activity of RFC
in tumours [4,11].
Transport protein structural information is a prerequisite for
understanding the mechanism of membrane transport. RFC
is a mammalian prototype of the MFS (major facilitator
superfamily) of transporters [4] that includes a large group
of carriers that mediate uptake of diverse substrates including
amino acids, neurotransmitters, sugars, vitamins, nucleosides
and organic phosphate [12]. MFS proteins typically contain
400–600 amino acids and a structural motif composed of
two halves, each with six transmembrane-spanning α-helices
connected by a large hydrophilic loop, and cytoplasmic N- and C-
termini. X-ray crystallographic structures of the bacterial MFS
proteins, lactose/proton symporter (LacY) [13] and inorganic
phosphate/glycerol-3-phosphate antiporter (GlpT) [14], were
reported in 2003 at resolutions of 3.5 Å (1 Å=0 . 1n m )a n d3 . 3Å
respectively. In both the LacY and GlpT structures, hydrophilic
cavities form substrate-binding sites from helices-I, -II, -IV and
-V of the N-terminal domain, and helices-VII, -VIII, -X and
-XI of the C-terminal domain. Helices-III, -VI, -IX and -XII are
embedded in the lipid bilayer and are not directly involved in
substrate binding.
By contrast, for mammalian MFS transporters such as RFC,
structural data are limited due to difﬁculties in isolating sufﬁcient
quantities of puriﬁed proteins and in crystallizing proteins
for X-ray diffraction studies. With hRFC (human RFC), we
used scanning cysteine mutagenesis to generate 282 mutants
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Figure 1 Two-dimensional structural model of hRFC
Atwo-dimensionalmodelforhRFCisshownbasedonthesolvedcrystalstructuresofLacYand
GlpT and scanning-cysteine accessibility methods [16]. The 12 TMDs of hRFC are divided into
twodistinctsegments,formingN-(TMD1–6)andC-(TMD7–12)terminalsix-helixbundles.At
the interface between the two segments, a hydrophilic cavity is formed from TMDs 1, 2, 4 and 5
oftheN-terminalsegmentandTMDs7,8,10and11oftheC-terminalsegment.TMDs3,6,9and
12 face the lipid bilayer and are not exposed to this aqueous cavity. Residues of the TMD5
andTMD8helicestargetedinourstudyforcysteine-scanningmutagenesisandcross-linkingare
numbered. Numbered positions in grey circles designate aqueous-accessible residues shown
by scanning cysteine accessibility methods in our previous publications [15,16]. Residues for
which cysteine substitutions result in non-functional mutant hRFCs [15,16] are indicated as
black squares. Lys411 in TMD11 is labelled as a black triangle, reﬂecting its unique role
in transport substrate binding, as reported previously [33].
with cysteine residues individually inserted into TMDs (trans-
membrane domains) 1–12 [15,16]. For the active 272 mutants,
aqueous accessibilities were conﬁrmed by monitoring transport
and protective effects of substrate [leucovorin or (6R,S)-5-formyl
tetrahydrofolate] upon treatment with membrane-impermeable
MTSES (2-sulfonatoethyl methanethiosulfonate). By homology
modelling from the solved structures for bacterial MFS proteins
and results of biochemical studies, a three-dimensional structural
model for the hRFC monomer was generated that includes
TMDs 1, 2, 4, 5, 7, 8, 10 and 11 as components of an aqueous
membrane-spanning translocation pathway ﬂanked by TMDs
3, 6, 9 and 12. A two-dimensional model of helix packing for
monomeric hRFC that incorporates these features is presented
in Figure 1. Most recently, hRFC monomers were found to form
homo-oligomers [17].
While powerful, scanning-cysteine accessibility methods pro-
vide only modest detailed information on the roles of individual
residues in substrate binding and/or membrane translocation, let
alone dynamic structural changes in the carrier that accompany
substrate binding. In our cysteine-scanning studies for hRFC,
the ten inactivating cysteine substitutions included a stretch of
residues in TMD4 (Arg
133,I l e
134,A l a
135,T y r
136 and Ser
138), Tyr
281
in TMD7, Ser
313 in TMD8 and Arg
373 in TMD10, suggesting their
functional or structural importance [16]. Of particular interest is
Ser
313, ﬂanking MTSES-reactive positions 311 and 314 in the
proximal (extracellular) end of TMD8 which lines the aqueous
transmembrane pathway for hRFC. In murine RFC, replacement
of the homologous Ser
309 with phenylalanine resulted in loss of
MTX transport and MTX resistance, although the extent of the
transport defect varied with different transport substrates [18].
In the present study, we use systematic site-directed muta-
genesis for Ser
313, and cysteine-insertion mutagenesis and
homobifunctional cross-linking between TMD8 and juxtaposed
TMD5 to explore the functional signiﬁcance of TMD8 and Ser
313
in membrane transport by hRFC. Our results indicate substantial
differencesbetweenvarious(anti)folatesubstratesintheirbinding
to hRFCs with mutated Ser
313, and in inducing conformational
changes involving the proximal end of TMD8 by protein cross-
linking, in direct support of a essential role for this region and
Ser
313 in binding and/or membrane translocation of (anti)folate
substrates.
MATERIALS AND METHODS
Reagents
[3
 ,5
 ,7-
3H]MTX (20 Ci/mmol) was purchased from Moravek
Biochemicals. The sources of the classical antifolate drugs were
as follows: MTX and aminopterin (Drug Development Branch,
National Cancer Institute, Bethesda, MD, U.S.A.); edatrexate
(10-ethyl-10-deazaaminopterin; CIBA-GEIGY Corporation);
PT523 [N
α-(4-amino-4-deoxypteroyl)-N
δ-hemiphthaloyl-L-orni-
thine from Dr Andre Rosowsky (Dana Farber Cancer Institute,
Boston, MA, U.S.A.)]; raltitrexed (N-{5-[N-(3,4-dihydro-2-
methyl-4-oxyquinazolin-6-ylmethyl)-N-methyl-amino]-2-thien-
oyl}-L-glutamic acid) and ZD9331 [(2S)-2-{O-ﬂuoro-p-[N-(2,7-
dimethyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-N-(prop-2-
ynyl)amino]benzamido}-4-(tetrazol-5-yl)-butyric acid] were
from AstraZeneca Pharmaceuticals; lometrexol [(6R)-5,10-
dideaza-5,6,7,8-tetrahydrofolate] and pemetrexed [N-{4-[2-
(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-
ethyl]benzoyl}-L-glutamic acid] (Alimta) were from Eli Lilly;
and GW1843U89 {(S)-2-[5-({[1,2-dihydro-3-methyl-1-oxo-
benzo(f)quinazolin-9-yl] methyl} amino)1-oxo-2-isoindolinyl]
glutaric acid} was from GlaxoSmithKline. Leucovorin and
folic acid were purchased from Sigma Chemical Company.
Both labelled and unlabelled MTX were puriﬁed by HPLC
prior to use [19]. Synthetic oligonucleotides were obtained
from Invitrogen. Tissue culture reagents and supplies were
purchased from assorted suppliers with the exception of fetal
bovine and iron-supplemented calf sera, which were purchased
from Hyclone Technologies. p-PDM (p-phenylenedimaleimide)
was purchased from Sigma Chemical Company and BMH
[1,6-bis(maleimido)hexane] was obtained from Pierce Chemical
Company.
Construction of cl-N6/C6 hRFC half-molecules with paired cysteine
residues and hRFC Ser313 mutants
The previously described HA (haemagglutinin)-tagged
TMD1–6 (N6) and Myc-tagged TMD7–12 (C6)h a l f -
molecule constructs in pcDNA3.1 and pcDNA3 respectively
[20], were used as templates to construct cysteine-less
(cl)N 6/C6 hRFC (cl-N6/C6) devoid of cysteine residues.
cl N6 (cl-N6) was prepared by replacing three cysteine residues
(at positions 30, 33 and 220) of N6 hRFC with serine by site-
directed mutagenesis using the QuikChange® kit (Stratagene).
cl C6 (cl-C6) hRFC was constructed by a combination of
restriction digestions and site-directed mutagenesis. First, the
SﬁI–NotI fragment of C6 hRFC in pcDNA3 was replaced with
the corresponding DNA fragment from full-length cl-hRFC
[21], resulting in replacement of three cysteine residues (at
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position 365, 396 and 458) with serine. The fourth cysteine
(at postion 246) was changed to serine by site-directed
mutagenesis. Using cl-N6 hRFC as a template, an analogous
approach was used to insert single cysteine residues into TMD5
(positions 160, 161, 163, 164, 167, 168, 171, 172, 174 and
175). Similarly, single cysteine residues were inserted into
TMD8 (311, 314, 315, 317, 318, 321, 322, 325 and 326) of
cl-C6 hRFC. Ser
313 mutants of hRFC were constructed by
site-directed mutagenesis from HA-tagged full-length wild-type
(wt)h R F C( h R F C
HA) [22] using the QuikChange® mutagenesis
kit. Mutagenesis primers are shown in Supplementary Table S1
(at http://www.BiochemJ.org/bj/430/430/bj4300265add.htm).
All mutations were conﬁrmed by DNA sequencing at the Wayne
State University DNA Sequencing Facility.
Cell culture and hRFC transfections
Transport-defective MTX-resistant HeLa cells, designated R5
[23], were a gift from Dr I. David Goldman (Albert Einstein
College of Medicine, Bronx, NY, U.S.A.). R5 cells were
maintained in RPMI 1640 medium, supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, penicillin (100 units/ml),
and streptomycin (100 μg/ml) in a humidiﬁed atmosphere at
37◦C in the presence of 5% CO2. Transient transfections of
wt and mutant hRFC constructs (see below) were performed
with Lipofectamine
TM Plus reagent (Invitrogen), as described
previously [15,16]. Cultures were split 24 h after transfection and
assayed for transport and expression on Western blots after an
additional 24 h.
TheMTXtransport-deﬁcientK562subline,designatedK500E,
was selected from wt K562 cells (American Type Culture
Collection) and maintained in complete RPMI 1640 medium
containing 10% iron-supplemented calf serum, 2 mM
L-glutamine,100 units/mlpenicillinand100 μg/mlstreptomycin,
and 0.5 μM MTX [24]. Wt and mutant hRFC constructs (see
below) were transfected into K500E cells by electroporation
(155 V, 1000 μF capacitance). After 24 h, cells were treated with
G418 (1 mg/ml) and stable clones were selected by cloning in
soft agar in the presence of G418 [24]. Both wt and transfected
K500E cultures were cultured in complete RPMI 1640 with
10% supplemented calf serum and antibiotics in a humidiﬁed
atmosphere at 37◦C in the presence of 5% CO2. For transfected
cells, the medium was supplemented with G418 (1 mg/ml).
Membrane transport assays
Uptake of [
3H]MTX (0.5 μM) in transiently transfected R5 HeLa
cells was measured over 2 min at 37◦Ci n6 0 m md i s h e si n
HSM buffer (Hepes/sucrose/Mg
2+ ‘anion-free’ buffer; 20 mM
Hepes and 235 mM sucrose, pH adjusted to 7.14 with MgO).
Uptake of [
3H]MTX was quenched with ice-cold Dulbecco’s
PBS. Cells were washed with ice-cold PBS (3 times) and proteins
were solubilized with 0.5 M NaOH. [
3H]MTX uptake into stably
transfected K500E cells was measured over 180 s (wt and
Ser
313 mutants) in physiological HBSS (Hank’s balanced salts
solution) in a shaking water bath at 37◦C, as described previously
[24,25]. For both cell line models, levels of intracellular
radioactivity were expressed as pmol/mg of protein, calculated
fromdirectmeasurementsof[
3H]MTXandproteincontentofcell
homogenates. Protein assays were based on the method of
Lowry et al. [26]. For the stable transfected K500E cells, kinetic
constants (Kt, Vmax) were calculated from Lineweaver–Burk plots
for[
3H]MTX,andKi valuesforassortedtransportsubstrateswere
determined from Dixon plots with [
3H]MTX (1 μM).
Preparation of plasma membranes and protein cross-linking
Transfected cells were harvested, ﬂash-frozen and stored at
−80◦C. Plasma membranes were prepared from the frozen cell
pellets asdescribedpreviously[25].Membranepreparationsused
for cross-linking were suspended in 20 mM Tris/HCl (pH 7.5)
containing 100 mM sucrose with a protease inhibitor cocktail
(Roche) at a protein concentration of 1–2 mg/ml. Otherwise,
membrane preparations were suspended in the aforementioned
buffer without sucrose. Membrane preparations were stored at
−80◦C as aliquots for further use.
Bothinvitro(plasmamembranes)andinvivo(transfectedcells)
cross-linkingreactionswereperformedat4◦Cor25◦Cwiththiol-
speciﬁc homobifunctional cross-linkers [p-PDM (10 Å; rigid)
or BMH (16 Å; ﬂexible)]. Final concentrations of cross-linkers
were 1 mM (in vitro cross-linking) or 0.25 mM (cross-linking
with intact cells) and treatments were for 30 min. Reactions
were terminated by adding 10 mM dithiothreitol. For the cell
treatments, following cross-linking, membranes were prepared.
In either case, membranes were diluted into SDS/PAGE sample
buffer [62.5 mM Tris/HCl (pH 6.8), 10% glycerol, 0.7% SDS
and0.7 M2-mercaptoethanol]andanalysedbySDS/PAGE(10%
gels) [15]. Proteins were transferred on to PVDF membranes
(Pierce) [15] and immunoblotted with Myc- or HA-speciﬁc
monoclonal antibodies (Covance) against epitope-tagged C6
and N6 hRFC proteins respectively, and anti-mouse secondary
IRDye
TM 800-conjugated antibody (Rockland). Detection and
densitometry used the Odyssey® IR imaging system and software
(LI-COR Biosciences).
For studies of substrate-induced conformational changes, cells
or membranes were incubated with transport substrates (1 mM
ﬁnal concentration) at room temperature (25◦C for 10 min and
1 h respectively), followed by cross-linking and immunoblotting,
as described above.
In some experiments, proteins were digested with N-glyco-
sidase F (New England Biolabs) prior to SDS/PAGE. For this,
membranes were collected by ultracentrifugation (48000 rev./
min; TLA 100.2 rotor and Beckman TL100 ultracentrifuge)
after cross-linker treatment and resuspended in 10 mM Tris/HCl
(pH 7.5) containing the protease inhibitor cocktail. Samples were
denatured for 10 min with 0.5% SDS and 40 mM dithiothreitol.
An equal volume of 50 mM sodium phosphate (pH 7.5) and
1% Nonidet P40 were added, along with N-glycosidase F
(1000 units), followed by incubation at 37◦C for 14 h. Control
samples were incubated in parallel in buffer without N-
glycosidase F. Samples were diluted with 3× SDS/PAGE sample
buffer, fractionated on 10% polyacrylamide gels, and analysed
by Western blotting.
RESULTS AND DISCUSSION
Functional impact of conservative and non-conservative
replacements of Ser313 in TMD8 of hRFC
Ser
313 is located in the proximal end of TMD8. In murine RFC,
replacement of Ser
309 (homologous with Ser
313 in hRFC) with
phenylalanine resulted in loss of transport and MTX resistance,
although the transport phenotype showed substantial substrate
dependence [18]. Replacement of Ser
313 in hRFC with cysteine
was inactivating [16].
To further explore the potential role of Ser
313 in binding and
translocation of hRFC substrates, we performed systematic site-
directed mutagenesis of this residue using HA-tagged wt hRFC
as a PCR template. Both conservative and non-conservative
replacements of Ser
313 were tested, including alanine, cysteine
and threonine, and results were compared with those for the
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Figure 2 Expression and transport function of Ser313 mutants
Transport activity and Western blotting results are shown for position 313 hRFC mutants
transiently transfected into R5 HeLa cells. In the inset are shown results for a Western blot
of hRFC proteins (2.5μg of protein) solubilized from membrane preparations from R5 HeLa
cells transiently transfected with wt and Ser313 mutant hRFC constructs. Detection was with an
HA-speciﬁc mouse antibody. Relative hRFC expression levels as determined by densitometry
are shown below each lane. In the main panel are shown uptake data for [3H]MTX (0.5μM)
over 2min at 37◦C, normalized to hRFC protein levels from Western blots. Transport results
are the means+ −S.E.M. for three separate experiments.
Table 1 MTX kinetic parameters for wt, S313A and S313T hRFCs
Data are means+ −S.E.M. for three separate experiments. For the normalized Vmax, Vmax/Kt
parameters, calculated Vmax values were normalized to relative hRFC levels on Western blots
(Supplementary Figure S1 at http://www.BiochemJ.org/bj/430/bj4300265add.htm), measured
by densitometry.
Vmax Normalized Vmax
Transfectant (pmol/mg of protein per min) Vmax Kt (μM) (normalized)/Kt
wt 4.62+ −0.37 4.62+ −0.37 1.89+ −0.43 2.44
S313A 0.50+ −0.04 0.41+ −0.03 2.26+ −0.44 0.18
S313T 0.81+ −0.14 0.91+ −0.16 2.11+ −0.54 0.43
phenylalanine hRFC mutant, based on the published report on
murine RFC [18]. All mutants were expressed in hRFC-null R5
HeLa cells at high levels on Western blots probed with an HA-
speciﬁc antibody (Figure 2, inset). However, when assayed for
transport with [
3H]MTX, all replacements were poorly tolerated.
When transport results were normalized to levels of hRFC
protein on Western blots, S313A and S313T preserved signiﬁcant
albeit low level activity over vector control-transfected cells with
activities ∼17% and ∼8% respectively, of that for wt hRFC
levels (Figure 2).
To characterize the role of Ser
313 in the speciﬁcity of substrate
binding to hRFC, we generated stable transfectants of the S313A
and S313T hRFC mutants in hRFC-null K562 (K500E) cells.
The levels of hRFC proteins for vector control K500E, and for
K500E cells transiently transfected with wt, S313A and S313T
hRFCs were measured on Western blots and are shown in
Supplementary Figure S1 (at http://www.BiochemJ.org/bj/430/
bj4300265add.htm). Kinetic constants (Kt, Vmax and Vmax/Kt,
including normalized values) for MTX with S313A and S313T
hRFC, along with results for wt hRFC, were calculated from
Lineweaver–Burke plots and are summarized in Table 1. The
results show that Kt values for MTX were minimally changed
from the wt values, whereas the Vmax values were substantially
decreased (Table 1).
Toextendourkineticanalysestoadditionaltransportsubstrates
with disparate structures, we used ten (anti)folate substrates
(raltitrexed, pemetrexed, leucovorin, folic acid, lometrexol,
Table 2 Ki values for (anti)folate substrates
Data are means+ −S.E.M. for three separate experiments. Statistically signiﬁcant differences
compared with Ki values for wt hRFC are noted as *P <0.05 and **P <0.005.
Ki (μM)
(Anti)folate wt S313A S313T
Raltitrexed 6.49+ −0.35 7.01+ −0.95 3.19+ −0.26*
Pemetrexed 17.39+ −1.10 8.80+ −0.93* 4.58+ −0.77*
Leucovorin 18.75+ −1.54 12.30+ −0.88* 7.74+ −0.66*
Folic acid 193.68+ −5.45 434.52+ −82.69* 237.29+ −58.38
Lometrexol 6.66+ −0.67 7.21+ −1.07 4.50+ −0.60
GW1843U89 2.10+ −0.01 2.61+ −0.50 0.75+ −0.06**
PT523 4.56+ −0.97 3.13+ −0.17 2.86+ −0.85
ZD9331 4.42+ −0.93 2.96+ −0.52 2.31+ −0.18
Aminopterin 7.03+ −0.02 3.43+ −0.58* 2.75+ −0.15**
Edatrexate 5.48+ −1.10 4.25+ −0.53 2.23+ −0.38
GW1843U89, PT523, ZD9331, aminopterin and edatrexate)
as competitive inhibitors of [
3H]MTX (1 μM) uptake over a
range of concentrations with wt, S313A and S313T hRFC-
expressing cells. Ki values were calculated from Dixon plots
(Table 2). Whereas Ki values for wt and mutant hRFCs
were essentially identical for lometrexol, PT523, ZD9331 and
edatrexate, statistically signiﬁcant differences in binding were
seen with other substrates. For instance, both S313A and
S313T showed signiﬁcantly decreased Ki values for pemetrexed,
leucovorin and aminopterin (∼2–3-fold) compared with those
for wt hRFC. S313T hRFC showed selectively increased binding
for raltitrexed and GW1843U89 compared with wt hRFC (∼2–
3-fold decreased Ki values), whereas S313A showed a ∼2-fold
increased Ki for folic acid compared with wt carrier. These results
supportthenotionthatSer
313 locatedintheproximalendofTMD8
of hRFC directly participates in (anti)folate binding.
Characterization of functional cl-N6/C6 hRFC half-molecule
transporter
TMDs 8 and 5 are juxtaposed in our hRFC monomer models
(Figure 1). We previously reported that cysteine substitutions at
multiple positions in TMD5 (Val
160,L e u
161,V a l
164,S e r
167,S e r
168,
Gly
171,G l n
172,V a l
175) and TMD8 (Ala
311,T h r
314) were reactive
with MTSES [16]. Although substrate protection from MTSES
was variable among these positions, the protection afforded
T314C was particularly notable (2.1-fold) [16]. These results
unambiguously established aqueous accessibilities for positions
spanning the entire length of TMD5 and in the proximal end of
TMD8 in hRFC, and they strongly implied that Thr
314 in TMD8
faces the substrate-binding pocket (Figure 1).
Our immediate goal was to express functional cl-hRFC as
TMD1–6 and TMD7–12 half-molecules (designated N6 and
C6 respectively) in hRFC-null R5 cells, cl-N6 with an HA
insertion after Glu
226 and cl-C6 with a Myc-His10 inserted
after Leu
537 (Figure 3A). For cross-linking, cl-N6 and cl-C6
hRFC constructs were mutated to include cysteine insertions
at deﬁned positions spanning the lengths of helices 5 and
8. This approach was based on our previous report that co-
expression of wt hRFC half molecules (wt-N6/C6) in hRFC-
null cultured human cells led to functional complementation and
restoration of transport activity, whereas transfections with the
N6 or C6 hRFC constructs individually were ineffective [20]. The
expressed HA-tagged hRFC N6 fragment was glycosylated at
Asn
58, resulting in a broadly banding (27–58 kDa) pattern on
SDS/PAGE that quantitatively reverted to a 27 kDa species upon
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Figure 3 Schematic diagrams of full length wt hRFC and hRFC-TMD1–6 and hRFC-TMD7–12 half molecules; expression and transport of cl-N6/C6 in R5 cells
(A) The upper panel shows a topology model for full-length wt hRFC, based on the predicted hRFC amino acid sequence including 12 TMDs, internally oriented N- and C-terminal domains, and
a cytosolic loop connecting TMDs 6 and 7. Amino acids are designated by the single letter abbreviations. The lower left-hand panel shows the structure of the hRFC TMD1–6 protein in which the
11 amino acid (YPYDVPDYAVN) HA epitope is inserted at position 226. The lower right-hand panel shows the structure of the hRFC TMD7–12 protein in which a Myc–His10 epitope is inserted at
position 537. This construct was also designed to include 18 amino acids (MVPSSPAVEDKQVPVEP) from the N-terminus of hRFC (designated N18 in the ﬁgure). The seven cysteine residues in
the hRFC half-molecule proteins are shown as black circles. (B) Western blot of membrane proteins (2.5 μg of protein) from R5 cells, and from R5 cells transfected with wt-N6/C6 and cl-N6/C6.
Detection involved anti-Myc antibody (upper panel) or anti-HA antibody (lower panel), and IRDye800-conjugated secondary antibody. The molecular mass in kDa is indicated on the left-hand side
of the gels. (C) Results for levels of [3H]MTX (0.5 μM) uptake in R5 cells and in R5 transfectants expressing cl-N6/C6 and wt-N6/C6. Transport results are expressed as the means+ −ranges for
duplicate experiments.
enzymicdeglycosylation,whereastheMyc-taggedhRFCC6 half-
molecule migrated as a sharp 40 kDa band on SDS/PAGE [20].
Confocal analysis showed that when co-expressed, both the N6
andC6 half-moleculesweretargetedtotheplasmamembranewith
no obvious intracellular staining [20].
We initially needed to prepare the cl-N6/C6 hRFC construct,
for which we used wt-N6/C6 hRFCs as a template for cysteine
replacements. cl half-molecule constructs were generated by
replacing cysteine residues at positions 30, 33 and 220 in N6,a n d
at positions 246, 365, 396 and 458 in C6 with serine (Figure 3A).
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cl-N6/C6 was co-transfected into hRFC-null R5 Hela cells to test
forrestorationoftransportfunctionandhRFCproteinexpression.
wt-N6/C6 was transfected in parallel as a positive control. At 48 h
post-transfection, cells were harvested for assays of [
3H]MTX
transport and levels of individual wt-a n dcl-N 6 and C6 proteins
on Western blots with antibodies against HA and Myc epitopes
respectively.
As shown in Figure 3(B) (lower panel), a major band migrating
at 30 kDa was detected with an anti-HA antibody (detects N6
hRFC) for both wt-N6/C6 and cl-N6/C6 hRFCs, along with an
assortment of higher molecular mass N-glycosylated N6 forms.
With the anti-Myc antibody (detects C6 hRFC; Figure 3B, upper
panel), a major 40 kDa band was detected for both wt-N6/C6 and
cl-N6/C6. An unidentiﬁed low abundant (∼38 kDa) species was
detectedwithanti-Mycantibodyinsomeanalyses.Althoughthere
were nominal differences in expression of N6 and C6 between wt-
and cl-hRFC proteins, MTX transport was somewhat decreased
(∼40%)f o rcl-N6/C6 (Figure 3C). Nonetheless, the MTX uptake
for cl-N6/C6 still exceeded (∼3-fold) the residual low level in R5
cells.
Preparation and cross-linking of N6/C6 hRFC with paired cysteine
residues in TMD5/TMD8
The use of functional cl-N6/C6 with each half-molecule including
a unique epitope tag and strategically placed cysteine insertions
provided an ideal approach for identifying cross-linked domains,
simply by following changes in migrations of HA- and Myc-
tagged proteins on Western blots. Although there may be
slight differences in folding between reconstituted half-molecule
transporters and full-length wt hRFC, wt-N6/C6 hRFC was shown
to accurately recapitulate a number of functional characteristics
of full-length wt hRFC [20].
Based on their relative proximities and proposed orientations
toward the hRFC hydrophilic cavity in two- (Figure 1) and three-
dimensional [16] models, cysteine residues were inserted into cl-
N6/C6 alongthejuxtaposedfacesofTMD5inN6 hRFC(positions
175, 174, 172, 171, 168, 167, 164, 163, 161 and 160) and of
TMD8 in C6 hRFC (positions 311, 314, 315, 317, 318, 321,
322, 325 and 326) (Figure 4A). Altogether, ten cysteine N6/C6
pairs (175/311, 174/314, 172/315, 171/317, 168/318, 167/321,
164/322, 163/325, 161/326 and 160/326 in TMDs 5/8) were
selected for transfections of hRFC-null R5 cells. All of the N6/C6
double cysteine mutants were expressed in R5 cells and the
six cysteine mutant pairs (175/311, 174/314, 172/315, 168/318,
164/322and160/326)withtransportactivitiesinexcess(2-fold)
ofthebasallowlevelinuntransfectedcells(SupplementaryFigure
S2 at http://www.BiochemJ.org/bj/430/bj4300265add.htm) were
used for cross-linking experiments (Figure 4A also shows a
schematic of the cysteine pairs used for cross-linking).
For the initial cross-linking experiments, plasma membranes
were prepared and cross-linked in vitro at 25◦C with the
membrane-permeable homobifunctional cross-linkers p-PDM
and BMH [27]. The proteins were separated by SDS/PAGE for
Western analysis with a Myc-speciﬁc antibody. In the absence
of cross-linkers, a prominent ∼40 kDa species was detected
(Figure 5A, lane 4 shows this result for the Cys
175/Cys
311 pair).
For the Cys
175 N6 and Cys
311 C6 mutant pair, treatment with cross-
linkers resulted in two major bands [70 and 80 kDa; labelled N6–
C6 and C6–C6 respectively, in Figures 4B (lanes 1 and 2) and 5A
(lanes5and6)]notseenintheabsenceofcross-linkers(Figure5A,
lane 4) or in cl-N6/C6 in the presence or absence of cross-linkers
(Figure 5A, lanes 1–3). With the other ﬁve mutants, identical
results were obtained in the absence of cross-linkers (results not
shown). Although a very low level of the 70 kDa N6–C6 was
Figure 4 Chemical cross-linking of double-cysteine mutants of TMDs 5/8
(A) Functional cysteine pairs for cross-linking are shown on TMD helices 5/8 from a
three-dimensional model of hRFC [16]. Paired cysteine residues that are cross-linked by
p-PDM or BMH are connected with a solid line. Cysteine pairs which exhibit no cross-linking
are connected with a broken line. (B) Western blots of cross-linked membrane samples of
cysteine pairs from TMD helices 5/8 treated with p-PDM and BMH. Cross-linking reactions
were performed with plasma membrane preparations in situ at 25◦C. The immunoblots were
probedwithanti-MycantibodyandIRDye800-conjugatedsecondaryantibody,andweredetected
as described in the Materials and methods section. C6 and cross-linked products (C6–C6 and
N6–C6) are indicated by arrows. p, p-PDM; B, BMH. The molecular mass in kDa is indicated
on the left-hand side of the gel.
detectedwithBMHandCys
160/Cys
326 withtheanti-Mycantibody,
for the other mutant pairs and cross-linkers, only the 80 kDa
(C6–C6) species was detected (Figure 4B). Explanations for the
failure to detect the 70 kDa band with these cysteine pairs range
from their relative inaccessibilities to the cross-linkers or helix
proximitiessomewhatdifferentfromthosepredictedbythethree-
dimensional hRFC model [16], to the impact of nearby amino
acids on individual cysteine chemical reactivities, all of which
may preclude an ability to efﬁciently cross-link, even though
individual cysteine residues may be highly reactive. From their
sizes, the 70 kDa and 80 kDa bands probably arose from cross-
links between the N6 and C6 half-molecules and between two C6
half-molecules respectively. There was no obvious difference in
the extent of cross-linking between p-PDM and BMH.
For the Cys
175/Cys
311 pair without cross-linker, HA-speciﬁc
antibody identiﬁed products derived from N6, including a major
∼30 kDaformandhighermassN-glycosylatedforms(Figure5A,
lower panel, lane 4). An identical pattern was seen with cl-
N6/C6 with or without cross-linkers (Figure 5A, lower panel,
lanes 1–3). With p-PDM/BMH treatments of Cys
175/Cys
311,t h e
70 kDa (but not 80 kDa) band was detected, along with a 60 kDa
species and higher molecular mass (glycosylated) forms not
seen in the absence of cross-linkers (Figure 5A, lower panel,
lanes 5 and 6). N-glycosidase F treatment shifted the major
HA immunoreactive bands from 70, 60 and 30 kDa to 67, 54
and 27 kDa respectively (Figure 5B, lanes 3 and 4), further
establishing their N-glycosylation and probable identities as N6–
C6,N 6–N6 and N6 respectively. N-glycosidase F treatment also
shifted the 70 kDa N6–C6 band detected with anti-Myc antibody
to 67 kDa but not the 80 kDa C6–C6 or the 40 kDa C6 bands
(results not shown). When probed with anti-HA antibody, the ﬁve
other cysteine pairs (174/314, 172/315, 168/318, 164/322 and
160/326) gave results identical with those for Cys
175/Cys
311 in the
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Figure 5 Validation of cross-linking with thiol-reactive homobifunctional cross-linkers
Chemical cross-linking of cl-N6/C6 and cl-N6/C6 including paired cysteine residues 175/311 from TMDs 5/8 was performed under a variety of conditions with p-PDM and BMH. Cross-linking
was performed as described in the Materials and methods section. Membrane proteins were solubilized and analysed on Western blots. (A) Upper panel: cross-linking of cl-N6/C6 and cl-N6/C6
half-molecules containing paired Cys175/Cys311 was performed on isolated plasma membranes under established conditions at 25◦C. The blot was probed with anti-Myc antibody. The C6 fragment
migratesat40kDaandthecross-linkedN6–C6 andC6–C6 speciesmigrateat70and80kDarespectively.Lowerpanel:theblotintheupperpanelwasstrippedandre-probedwithananti-HAantibody.
The major band corresponding to the N6 fragment migrates as 30kDa and the cross-linked N6–N6 and N6–C6 species migrate at approx. 60 and 70kDa respectively. The molecular mass in kDa is
indicatedontheleft-handside.(B)Deglycosylationofcross-linkedproteinswithN-glycosidaseF.PlasmamembranesfromR5cellstransfectedwiththeCys175/Cys311 half-moleculeconstructswere
either untreated or cross-linked with p-PDM at 25◦C, followed by digestion with or without N-glycosidase F. The immunoblot was probed with an HA-speciﬁc antibody and IRDye800-conjugated
secondary antibody. (C) Controls for the cross-linking reaction are shown including: I, cross-linking at 25◦C of plasma membranes containing cysteine pair 175/311 under established conditions
(lanes 1 and 2); and II, Cys175/Cys311 plasma membranes solubilized with 0.7% SDS before cross-linker treatment at 25◦C, followed by treatment with cross-linkers for 30min and quenching with
10 mM dithiothreitol and SDS/PAGE buffer (lanes 3 and 4). The immunoblot was probed with an anti-Myc antibody. (D) Results are shown for cross-linking at 4◦C and 25◦C with isolated plasma
membranes from transfected R5 cells expressing paired Cys175/Cys311 half-molecules (upper panel) or intact transfected cells (lower panel) under established conditions at 4◦C and 25◦C. The
immunoblot was probed with an anti-Myc antibody. (E) Results are shown for cross-linking at 4◦C with intact transfected R5 cells expressing cl-N6 and Cys311 C6 half-molecules. The immunoblot
was probed with an anti-Myc antibody. p, p-PDM;B, BMH; NT, no treatment; PNGase, N-glycosidase F.
absence of cross-linking. Upon cross-linking, the 60 kDa species
was detected (results not shown). Our inability to detect higher
molecular mass (>70 kDa) glycosylated forms of N6–C6 on blots
probed with anti-Myc antibody probably reﬂects differences in
sensitivities between anti-Myc antibody and anti-HA antibody
(as suggested from the more intense signal for the 70 kDa species
with anti-HA over anti-Myc antibodies in Figure 5A).
Several critical controls were performed for our in vitro cross-
linkingexperiments.WhenthereactionsforCys
175/Cys
311 mutants
were performed at 4◦C rather than 25◦C, cross-links were still
detected(Figure5D,upperpanel,lanes1and3).Anothernegative
control involved solubilization of the Cys
175/Cys
311 membranes
with 0.7% SDS before cross-linker treatment, followed by
treatment with cross-linkers for 30 min at 25◦C, and quenching
with 10 mM dithiothreitol and SDS/PAGE buffer (labelled II
in Figure 5C, lanes 3 and 4). Results were compared with
those for the Cys
175/Cys
311 sample cross-linked under established
conditions at 25◦C (labelled I in Figure 5C, lanes 1 and 2). For
reaction II, neither the 70 kDa nor 80 kDa cross-linked band was
detected (with anti-Myc antibody), ﬁrmly establishing that the
cross-linking detected with the Cys
175/Cys
311 half-molecules does
not occur randomly in solution but rather can only occur in situ
in the intact plasma membranes.
Cross-linking of the 175/311 cysteine pairs was also conﬁrmed
with intact cells co-transfected with Cys
175 N6 and Cys
311 C6 half-
molecule constructs treated with p-PDM and BMH at 4◦Ca n d
25◦C. In membrane preparations from cross-linked cells, both
C6–C6 and N6–C6 cross-linked species were detected on Western
blots (Figure 5D, lower panel). In cells co-transfected with the
cl-N6 and Cys
311 C6 half-molecule constructs and treated with
p-PDM at 4◦C, the 80 kDa band (but not the 70 kDa band) was
detected (Figure 5E, lane 1). This unambiguously establishes that
the80 kDaspecies(butnotthe70 kDaform)istheresultofcross-
linksbetweenCys
311 onseparateC6 moleculesandthatthe70 kDa
cross-linked product is absolutely dependent on co-expression of
the Cys
175 N6 and Cys
311 C6 hRFC half-molecules.
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Our cross-linking results strongly suggest that the TMD5 and
TMD8 helices are close together at their proximal (extracellular)
ends, as indicated by formation of the N6–C6 cross-link between
Cys
175 and Cys
311. Detection of C6–C6 intermolecular cross-links
for multiple cysteine pairs spanning TMDs 5 and 8 suggests that
the TMD8 helix in each hRFC half-molecule protomer abuts the
corresponding region in another, in support of the notion of
higher-order hRFC homo-oligomers, as recently reported [17].
An analogous argument can be made for the apparent N6–
N6 intermolecular cross-links for the Cys
175/Cys
311 pair and
TMD5. While the formation of C6–C6 (or N6–N6) cross-links
was completely unexpected given that the positions selected for
cysteine replacement were based on their patterns of MTSES
reactivities and apparent aqueous accessibilities, the nature of the
homo-oligomeric interface(s) is not yet established. Studies are
underway to explore this important question.
Effects of ligand binding on TMD5/TMD8 cross-linking as a
sensitive probe of conformationally active interfaces
If Ser
313 directly participates in substrate binding as suggested by
our mutant studies, nearby residues (e.g. position 311) might
be expected to be conformationally active in the presence of
excess substrate. To test this possibility, in situ cross-linking
involving position 311 was used as a highly sensitive probe of
the conformationally active interfaces between transmembrane
helices 8 and 5 upon substrate binding [28–30]. We transfected
R5 cells with Cys
175 N6 and Cys
311 C6 hRFC, then treated
the cells with BMH in the absence and presence of hRFC
substrates (aminopterin, leucovorin and raltitrexed). In four
independent experiments, N6–C6 (but not C6–C6) cross-links by
BMH were demonstrably increased to 1.6-, 2.3- and 2.4-fold by
leucovorin, aminopterin and raltitrexed respectively (Figure 6).
Analogous results were observed with BMH-treated plasma
membranes from Cys
175/Cys
311-transfected cells, cross-linked in
the presence of transport substrates (Supplementary Figure S3 at
http://www.BiochemJ.org/bj/430/bj4300265add.htm).
Since cross-link formation is a reﬂection of dynamic collisions
that result in chemical modiﬁcations of reactive residues [31],
our ﬁnding of enhanced cross-linking between positions 175
and 311 in the presence of transport substrates suggests that
conformational changes occur involving the proximal end of
TMD8 in relation to TMD5 upon substrate binding. This is
entirely consistent with the notion that this stretch of TMD8
contributes to the substrate-binding pocket in hRFC, as noted
above.
Conclusions
Although hRFC exists as an homo-oligomer [17], each hRFC
monomer has its own translocation pathway and appears to
functionindependently[32].Characterizationofthedeterminants
of substrate binding in each hRFC monomer is essential to under-
standing the molecular mechanism of folate and antifolate mem-
brane transport by this physiologically and pharmacologically
important carrier. We previously proposed that Lys
411 in TMD11,
Arg
373 inTMD10,Tyr
281 inTMD7andSer
313 inTMD8participate
in (anti)folate binding and that TMD helices including these
residues comprise the hRFC substrate-binding pocket [16]. Thus
replacement of Arg
373,T y r
281 or Ser
313 in hRFC individually with
cysteineresultedinnearlycompletelossoftransportactivity[16].
Similarly, aliphatic substitutions of Arg
373 abolished transport,
whereas activity was preserved with lysine replacement at this
position [33]. Although Lys
411 in hRFC can be replaced by any
Figure 6 Effects of ligand binding on TMD5/TMD8 cross-linking
IntactR5HeLacellsweretransfectedwithpairedCys175/Cys311 hRFChalf-molecules,pre-treated
with or without 1mM aminopterin, leucovorin or raltitrexed at 25◦C for 10min, followed by
chemical cross-linking with BMH. The immunoblots were probed with an anti-Myc antibody
and IRDye800-conjugated secondary antibody. Detection and densitometry were performed as
described in the Materials and methods section. C6 and cross-linked products (C6–C6 and
N6–C6) are noted with arrows. In the lower panel, the blot was stripped and reprobed with an
antibodyagainstNa+/K+-ATPaseasaloadingcontrol(mouseantibodyfromNovusBiologicals).
MeandensitometrymeasurementsoftheintensitiesoftheN6–C6 cross-linkedband(normalized
to respective loading controls) from four independent experiments are shown below each lane.
Relative S.E.M. values were 0.10, 0.10 and 0.25 respectively for the leucovorin, aminopterin
and raltitrexed treatments and P values compared with the no treatment were all less than 0.01,
as measured using a paired t test. The molecular mass in kDa is indicated on the right-hand
side of the gel.
of a number of amino acids of varying bulk and charge with
modesteffectsontransportactivity,thisresidueisnonethelessthe
primary target for electrophilic attack by N-hydroxysuccinimide-
activated MTX ester and can participate in an interaction with
(anti)folate substrate, primarily through an ionic association with
the γ-carboxy group [33]. However, this interaction with Lys
411
is apparently not essential for transport function since the γ-
carboxy group is not only expendable, but indeed its replacement
by an uncharged hydrogen or methyl group in a series of
furo[2,3-d]pyrimidine antifolates actually enhanced high-afﬁnity
reversiblebindingofsubstratetothecarrier,aslongasanionizable
α-carboxy group is intact [33]. Rather, Arg
373 was suggested to
forge an ionic association with the α-carboxylate of (anti)folate
substrates [33].
The present study sheds new important light on the functional
signiﬁcance of the proximal TMD8 helix in general, and
Ser
313 in particular. By kinetic analysis with an assortment of
structurally diverse transport substrates, there were substrate-
selective differences in Ki values between wt and Ala/Thr
313
mutant hRFCs, suggesting a possible role for Ser
313 in substrate
binding to hRFC.
OurresultswithCys
175/Cys
311 hRFChalf-moleculemutantsand
cysteinecross-linkingestablishedthattheproximal(extracellular)
ends of the TMD8 and 5 helices are juxtaposed, as predicted by
hRFC homology models. Although cross-linking results must be
interpreted with caution since cross-link formation is a reﬂection
of dynamic movements and chemical reactivities with individual
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Figure 7 Hypothetical model of the hRFC binding pocket
A hypothetical model is shown for MTX binding to the proposed hRFC binding pocket. In
this model, a MTX molecule (represented as green and blue sticks) was manually inserted
into the hRFC substrate-binding pocket including Tyr281,S e r 313,A r g 373 and Lys411,u s i n gt h e
three-dimensional hRFC model described in our previous report [16]. Depicted are proposed
interactions between the pteridine ring of MTX and Tyr281 and Ser313, between the α-carboxy
and Arg373, and between the γ-carboxy and Lys411. The estimated distances between the MTX
molecule and the Ser313,A r g 373 and Lys411 side chains are noted.
cysteine residues rather than just their proximities [31], this
approach has nonetheless established a close correlation between
collision rates and residue proximities [34]. In the presence of
transport substrates, the 175/311 interface was conformationally
active, as reﬂected in increased N6–C6 cross-links between these
positions. Thus while position 311 is not directly involved
in substrate binding [16], this result nonetheless supports the
notion that residues located in this stretch of TMD8 (i.e. Ser
313)
participate in substrate binding. Cross-linking between Cys
175
and Cys
311 was substrate-dependent, further implying that hRFC
assumes distinct conformations in this region upon binding
different transport substrates, consistent with our kinetic analysis
of structurally diverse transport substrates.
Basedonthesecollectivedata,wepresentahypotheticalmodel
for binding (anti)folate substrates to hRFC involving interactions
between the pteridine ring of MTX and Tyr
281 and Ser
313,a n d
between the α-carboxy of MTX and Arg
373 (Figure 7). Although
a putative hydrogen bond is depicted between the Ser
313 hydroxy
group and the 4-amino group of MTX,this must not be obligatory
since functionality at position 313 can in part met by alanine. In
the model, Tyr
281 is juxtaposed to the pteridine ring of MTX and
may bind with MTX through π–π interactions. Lys
411 interacts
with the γ-carboxy group of MTX, although this is not essential
for binding and transport, as noted above.
Finally, results are presented herein that C6–C6 and N6–N6
cross-links occur for the TMD5/8 cysteine pairs, providing
further independent conﬁrmation of the existence of homo-
oligomeric hRFC [17]. As previously suggested, such higher-
order hRFC structures should be particularly signiﬁcant, with
profound implications to hRFC mechanism, regulation and
antifolateresistance[17].Furthercharacterizationofthestructural
and regulatory features of homo-oligomeric hRFC will be the
topic of future reports.
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determined by site-directed mutagenesis and protein cross-linking
Zhanjun HOU*, Jianmei WU*, Jun YE†, Christina CHERIAN* and Larry H. MATHERLY*†‡§1
*Developmental Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, U.S.A., †Department of Biochemistry
and Molecular Biology, Wayne State University School of Medicine, Detroit, MI 48201, U.S.A., ‡Graduate Program in Cancer Biology, Wayne State University School of Medicine,
Detroit, MI 48201, U.S.A., and §Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201, U.S.A.
FigureS1 Expressionofwt,S313AandS313ThRFCinK500E(K562)stable
clones
Results are shown for a Western blot of plasma membrane proteins (10 μg of protein)
from hRFC-null K500E cells stably transfected with wt hRFC, S313A hRFC and S313T hRFC.
hRFC proteins were detected with an HA-speciﬁc mouse antibody and secondary IRDyeTM
800-conjugated antibody. Detection and densitometry of the blots was performed with the
Odyssey® Imaging System. The relative hRFC expression level as determined by densitometry
is shown below each lane.
Figure S2 Transport activity for cl- and cysteine-insertion N6/C6 half
molecules
Results are shown for levels of [3H]MTX uptake in R5 cells and in R5 transfectants expressing
cl-N6/C6 and double cysteine mutants. [3H]MTX (0.5 μM) uptakes were measured for 2 min at
37◦C.
Figure S3 Effects of ligand binding on TMD5/TMD8 cross-linking
Plasma membrane preparations of transfectant of Cys175/Cys311 hRFC half-molecules were
pretreatedwithorwithout1mMaminopterin,leucovorinorraltitrexedat25◦Cfor1h,followed
by chemical cross-linking with BMH at 25◦C for 30 min. The immunoblots were probed with
anti-Myc antibody and IRDye800-conjugated secondary antibody. Detection and densitometry
were performed as described in the Materials and methods section of the main text. C6 and
cross-linkedproducts(C6–C6 andN6–C6)arenotedwitharrows.Inthelowerpanel,theblotwas
stripped and reprobed with an antibody against Na+/K+-ATPase as a loading control (mouse
antibody from Novus Biologicals). Mean values of N6–C6 (normalized to loading control) from
four independent experiments are shown below each lane of the image. Relative S.E.M. values
were 0.24, 0.18 and 0.30 respectively for the leucovorin, aminopterin and raltitrexed treatments
and P values compared with the no treatment were all less than 0.02, as measured using a
paired t test. The molecular mass in kDa is indicated on the right-hand side.
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Table S1 Primer pairs used for construction of cl-N6,C 6 hRFC, cysteine-
substituted mutants and Ser313 mutants
Primers Forward/reverse Sequences (5  →3 )
C30S/C33S Forward CGGCGCCTCGTGAGCTACCTTAGCTTCTACGGCTTC
C30S/C33S Reverse GAAGCCGTAGAAGCTAAGGTAGCTCACGAGGCGCCG
C220S Forward CGACCGGGGGCGGAGCGAAACCTCGGCTTC
C220S Reverse GAAGCCGAGGTTTCGCTCCGCCCCCGGTCG
C246S Forward CCCTGCGGGTGGCCAGTGGGGACTCAGTGC
C246S Reverse GCACTGAGTCCCCACTGGCCACCCGCAGGG
V160C Forward TCGCGCGCTGCGTGTCTGCTGGGCGTG
V160C Reverse CACGCCCAGCAGACACGCAGCGCGCGA
L161C Forward CGCGCTGCGGTGTGTCTGGGCGTGTTC
L161C Reverse GAACACGCCCAGACACACCGCAGCGCG
G163C Forward GCGGTGCTGCTGTGCGTGTTCACC
G163C Reverse GGTGAACACGCACAGCAGCACCGC
V164C Forward GTGCTGCTGGGCTGCTTCACCAGCTCC
V164C Reverse GGAGCTGGTGAAGCAGCCCAGCAGCAC
S167C Forward GGCGTGTTCACCTGCTCCGTGCTG
S167C Reverse CAGCACGGAGCAGGTGAACACGCC
S168C Forward GTGTTCACCAGCTGCGTGCTGGGC
S168C Reverse GCCCAGCACGCAGCTGGTGAACAC
G171C Forward AGCTCCGTGCTGTGCCAGCTGCTG
G171C Reverse CAGCAGCTGGCCGCACACGGAGCTGGT
Q172C Forward TCCGTGCTGGGCTGTCTGCTGGTCACT
Q172C Reverse AGTGACCAGCAGACAGCCCAGCACGGA
L174C Forward CTGGGCCAGCTGTGTGTCACTGTGGGC
L174C Reverse GCCCACAGTGACACACAGCTGGCCCAG
V175C Forward GGCCAGCTGCTGTGCACTGTGGGCCGA
V175C Reverse TCGGCCCACAGTGCACAGCAGCTGGCC
A311C Forward GCGGCAGATTGTGCCTCCACGCTGC
A311C Reverse GCAGCGTGGAGGCACAATCTGCCGC
T314C Forward GATGCTGCCTCCTGTCTGCTGGGCG
T314C Reverse CGCCCAGCAGACAGGAGGCAGCATC
L315C Forward GCCTCCACGTGCCTGGGCGCCATCAC
L315C Reverse GTGATGGCGCCCAGGCACGTGGAGGC
G317C Forward TCCACGCTGCTGTGTGCCATCACGTCC
G317C Reverse GGACGTGATGGCACACAGCAGCGTGGA
A318C Forward CTGCTGGGCTGCATCACGTCCTTCGC
A318C Reverse GCGAAGGACGTGATGCAGCCCAGCAG
S321C Forward GCCATCACGTGCTTCGCCGCGGGCTTCG
S321C Reverse CGAAGCCCGCGGCGAAGCACGTGATGGC
F322C Forward GCCATCACGTCCTGCGCCGCGGGCTTCG
F322C Reverse CGAAGCCCGCGGCGCAGGACGTGATGGC
G325C Forward TCCTTCGCCGCGTGCTTCGTGAAGATCCGC
G325C Reverse GCGGATCTTCACGAAGCACGCGGCGAAGGA
F326C Forward TTCGCCGCGGGCTGTGTGAAGATCC
F326C Reverse GGATCTTCACACAGCCCGCGGCGAA
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